CPA4 and familial pancreatic carcinoma: It has been reported to involve in prostate cancer aggressiveness.26 In pancreatic cancer, CPA4 was significantly overexpressed and closely related to tumour progression and poor prognosis.27 In gastric cancer, CPA4 was highly expressed and could be an independent poor prognostic factor.28 In non–small‐cell lung cancer, high CPA4 expression is related to poor outcome and could be used in early detection.29 In breast cancer, CPA4 was reported to be a prognosis marker and therapeutic target.30 However, CPA4 expression and clinical significance in glioma have not yet been reported.